The global pharmacovigilance market, valued at approximately USD 7.95 billion in 2024, is expected to reach around USD 11.78 billion by 2030, expanding at a compound annual growth rate of about 6.5 percent.
Pharmacovigilance is no longer confined to compliance-driven adverse event reporting. It has become a critical function that directly influences product lifecycle strategy, regulatory positioning, and patient safety outcomes. As healthcare systems grow more complex and therapies become more specialized, organizations are rethinking how they approach safety monitoring at scale.
A major driver behind this shift is the steady rise in adverse drug reactions (ADRs). Increased use of combination therapies, along with higher instances of drug misuse, has led to a noticeable surge in safety events across global markets. This growing volume of data is pushing organizations to move beyond traditional methods and adopt more intelligent, technology-enabled frameworks.
Market indicators reflect this transformation clearly. The global pharmacovigilance market, valued at approximately USD 7.95 billion in 2024, is expected to reach around USD 11.78 billion by 2030, expanding at a compound annual growth rate of about 6.5 percent. This growth is not just volume-driven; it signals a deeper shift toward integrated, insight-led safety systems that support faster and more confident decision-making.
Technology, Real-World Data, and the New Safety Ecosystem
The increasing reliance on real-world evidence is reshaping pharmacovigilance operations. Data from electronic health records, patient registries, and digital health tools is now being incorporated into safety assessments. This allows organizations to detect patterns that may not emerge during controlled clinical trials, especially in diverse patient populations.
At the same time, artificial intelligence and automation are redefining how safety data is processed. Case intake, signal detection, and literature screening are becoming more efficient through machine learning models and natural language processing. Instead of reacting to risks after they escalate, companies can now identify early warning signals and act proactively.
Cloud-based platforms are also enabling better collaboration across global teams. With regulatory expectations continuing to evolve, having centralized, transparent, and audit-ready systems is no longer optional. This is where experienced pharmacovigilance service providers play a key role, helping organizations scale operations while maintaining compliance across multiple regions.
A recent example highlights how technology partnerships are accelerating this transformation. In April 2025, Parexel partnered with Palantir to strengthen clinical trial delivery. By integrating Palantir’s Foundry and Artificial Intelligence Platform into its data systems, Parexel aims to improve trial efficiency, enhance data transparency, and reduce time-to-market for new therapies. Such collaborations demonstrate how pharmacovigilance is becoming deeply interconnected with clinical and data ecosystems.
Industry Landscape and Strategic Partnerships
As the demand for advanced safety solutions grows, several global players are shaping the direction of the pharmacovigilance market. These organizations are investing heavily in digital capabilities, analytics, and end-to-end service models to meet evolving client needs.
Key pharmacovigilance companies include:
These companies collectively influence how pharmacovigilance services are delivered, particularly in areas such as automation, regulatory compliance, and global scalability.
Building Future-Ready Pharmacovigilance Strategies
Organizations that want to stay competitive must rethink how pharmacovigilance fits into their broader operating model. It is no longer a standalone function but an integrated capability that connects clinical development, regulatory affairs, and commercial strategy.
Working with the right pharmacovigilance service providers can help address several critical challenges. These include managing increasing case volumes, ensuring compliance across jurisdictions, and leveraging advanced analytics without overburdening internal teams. Service providers with strong digital capabilities and therapeutic expertise are especially valuable in navigating this complexity.
Looking ahead, the focus will continue to shift toward predictive safety, where risks are identified before they impact patients or regulatory outcomes. Companies that invest in data integration, intelligent automation, and strategic partnerships will be better positioned to manage uncertainty and accelerate innovation.
Pharmacovigilance is no longer just about safety reporting. It is about enabling safer, faster, and more efficient healthcare delivery in an increasingly data-rich world.